43 results about "Chronic pulmonary heart disease" patented technology

The invention relates to a Chinese medicament for treating chronic obstructive emphysema and pulmonary heart disease, which comprises the following crude herbal materials (by weight portion): chastetree fruit 15-25 parts, apricot kernel 5-15 parts, pinellia tuber 12-20 parts, schisandra fruit 10-35 parts, Sichuan fritillary bulb 8-35 parts, rhizome of Sichuan lovage 12-20 parts, red sage root 15-30 parts, root of balloonflower 5-15 parts, mulberry bark 8-30 parts, coltsfoot flower 10-18 parts, astragalus root 15-30 parts, pilose asiabell root 10-40 parts, ginkgo nut 12-20 parts, trichosanthes anguina 20-35 parts, white atractylodes rhizome 10-20 parts, Chinese angelica root 15-35 parts, poria cocos wolf 10-30 parts, honeysuckle flower 10-30 parts, coptis root 5-15 parts, golden buckwheat rhizome 10-30 parts, ledebouriella root 9-30 parts, licorice root 5-20 parts, dried peach 12-30 parts, wild or spiny jujuba seed 10-30 parts, pearl 6-15 parts.

The invention discloses traditional Chinese medicine composition for treating chronic pulmonary heart disease and a preparation method of the traditional Chinese medicine composition. The traditionalChinese medicine composition comprises traditional Chinese medicine raw materials in parts by weight as follows: 6-9 parts of herba ephedrae, 3-6 parts of herba asari, 10-15 parts of herba schizonepetae, 10-20 parts of radix saposhnikoviae, 10-20 parts of rhizoma zingiberis, 10-25 parts of fructus schisandrae, 20-30 parts of flos lonicerae, 10-15 parts of fructus forsythiae, 20-30 parts of gypsumfibrosum, 10-15 parts of radix scutellariae, 10-15 parts of cortex mori, 10-20 parts of rhizoma phragmitis, 10-15 parts of semen coicis, 8-15 parts of semen benincasae, 10-20 parts of semen armeniacaeamarum, 15-20 parts of radix scrophulariae, 10-15 parts of caulis bambusae in taenia and 6-10 parts of radix glycyrrhizae. The disclosed traditional Chinese medicine composition is reasonable in compatibility, has no toxic or side effects, has functions of moistening lung to arrest cough, reducing swelling, resolving mass, clearing away heat, purging pathogenic fire and dredging heart-lung, has agood curative effect on the chronic pulmonary heart disease and takes effect quickly, the course of treatment is short, and the disease is not prone to relapse.

The invention relates to novel pharmacological action of traditional Chinese medicine salvianolic acid A and application thereof in the preparation of products for preventing, relieving and / or treating pulmonary arterial hypertension and its complications. The salvianolic acid A has the advantages that the salvianolic acid A has the pharmacological action of relieving pulmonary circulation pressure rise, the pharmacological actions of relieving right heart failure due to pulmonary arterial hypertension, improving right ventricular hypertrophy and right ventricular enlargement, improving heart injury due to pulmonary arterial hypertension, and restoring from heart failure, and the pharmacological actions of lowering endothelin-1 level in pulmonary tissues, relieving pulmonary arterial remodeling and improving pathologic damage of pulmonary tissues; the salvianolic acid A is a monomer compound extracted from Salvia miltiorrhiza, has low toxicity, has a wide source range of material, has promising application and development prospect, is an ideal novel traditional Chinese medicine monomer for treating pulmonary arterial hypertension and its complications, and may be applied to prepare products for preventing, relieving and treating pulmonary arterial hypertension and its complications, such as chronic obstructive pulmonary emphysema, chronic pulmonary heart disease and heart failure.

The invention discloses a traditional Chinese medicine composition for treating a chronic pulmonary heart disease. The traditional Chinese medicine composition is prepared from the following raw materials by certain weight ratios: ephedra, cassia twig, rhizoma zingiberis, asarum, pinellia ternate, schisandra chinensis, white peony root, rhizoma belamcandae, semen lepidii, astragalus membranaceus, angelica sinensis, rhodiola rosea, gecko, agarwood, peach seed, flos carthami, ligusticum wallichii, salviae miltiorrhizae, spina gleditsiae, codonopsis pilosula, roasted rhizoma atractylodis macrocephalae, poria cocos and honey-fried licorice root. The traditional Chinese medicine composition has the efficacies of eliminating dampness, removing phlegm, freeing the lung, relieving asthma, nourishing the blood for tranquilization, supplementing qi and promoting the production of body fluid. The traditional Chinese medicine composition is capable of effectively treating the chronic pulmonary heart disease.

The invention provides a traditional Chinese medicine composition for treating chronic pulmonary heart disease in the stable phase. The composition is prepared from radix aconite lateralis preparata, cassia twig, cinnamon, herba epimedii, raw ginger, astragalus membranaceus, semen lepidii, earthworm, angelica sinensis, poria cocos, schisandra chinensis, rhizoma atractylodis macrocephalae, pericarpium citri reticulatae, salviae miltiorrhizae and fructus psoraleae. The composition is researched, processed and developed according to a local traditional method, does not have toxic or side effect, is safe and reliable, and has remarkable effect; and the preparation method is simple and feasible, and the raw materials are easily available. The traditional Chinese medicine composition has the effects of tonifying qi and yin without grease, warming yang and promoting inspiration without dry-heat, can be used for comprehensively achieving the functions of nourishing lung, tonifying kidney, strengthening spleen, warming yang, promoting inspiration, relieving asthma, promoting blood circulation to remove stasis, and can hit the pathogenesis of the chronic pulmonary heart disease in the stable phase. The traditional Chinese medicine composition is mainly used for treating chronic pulmonary heart disease in the stable phase.

The invention provides a traditional Chinese medicine composition for treating the chronic pulmonary heart disease. The composition comprises the following traditional Chinese medicines by mass: 9 parts of ginseng, 5 parts of cordyceps militaris, 6 parts of prepared monkshood, 15 parts of prepared rehmannia root, 10 parts of mulberry bark, 5 parts of ephedra stem, 8 parts of honeysuckle flower, 10 parts of dried orange peel and 10 parts of Poria cocos. The traditional Chinese medicine composition for treating the chronic pulmonary heart disease mainly uses kidney-tonifying, qi-benefiting, heat-clearing, detoxifying, antibacterial and antiphlogistic traditional Chinese medicines and has a substantial curative effect.

The invention discloses a traditional Chinese medicine composition for treating chronic pulmonary heart disease, belonging to the technical field of medicines for treating chronic pulmonary heart disease. The traditional Chinese medicine composition comprises the following components in parts by weight: 8-12 parts of negundo chastetree fruit, 8-12 parts of ephedra sinica, 8-12 parts of cassia twig, 8-12 parts of radix bupleuri, 8-12 parts of angelica decursiva, 8-12 parts of radix paeoniae rubra, 8-12 parts of radix paeoniae alba, 8-12 parts of elecampane, 8-12 parts of ligusticum wallichii, 8-12 parts of acorus gramineus soland, 8-12 parts of semen lepidii, 8-12 parts of agastache rugosus, 8-12 parts of lumbricus, 4-8 parts of asarum, 4-8 parts of wild ginger, 4-8 parts of mint, 4-8 parts of rhizoma zingiberis, 4-8 parts of aconitum carmichaelii, 8-12 parts of rhizoma belamcandae, 8-12 parts of thorny elaeagnus leaf, 8-12 parts of coltsfoot, 4-8 parts of periostracum cicada, 8-12 parts of pericarpium citri reticulatae, 8-12 parts of fleece-flower root, 8-12 parts of poria cocos, 4-8 parts of honey-fried licorice root, 8-12 parts of the root of red-rooted salvia and 8-12 parts of amethyst. The traditional Chinese medicine composition disclosed by the invention is wide in drug source coverage, scientific in compatibility, obvious in curative effect and fast in effectiveness, directly reaches the deep focus, regulates the internal functions of the human body and does not have any toxic or side effect.

The invention provides a traditional Chinese medicine for treating the chronic pulmonary heart disease. The traditional Chinese medicine comprises the following raw materials: astragalus mongholicus, ligusticum wallichii, codonopsis pilosula, radix paeoniae rubra, peach kernel, platycodon grandiflorum, the root bark of white mulberry, perilla fruit, the fruit of Chinese magnoliavine, thunberg fritillary bulb, leech, liquorice and the like. The above raw materials are soaked with water for 30 min according to the volume ratio of 1:5 and are decocted for 30 min for twice; filtering is carried out for twice to obtain 300 ml of decoction; a patient takes the decoction for once respectively in the morning and in the evening and takes a dose of the traditional Chinese medicine every day. By clinical verification, the traditional Chinese medicine can relieve symptoms, improve life quality of the patient, enhance the immune function of the patient, reduce morbidity, delay progressive disease and obtain a good curative effect.

The invention is a pulse-activating sustained-release capsule and the preparing method thereof, belonging to the field of traditional Chinese medicine and preparing method, using gen-seng, Dwarf Lilyturf Tuber and Chinese Magnoliavine Fruit as raw medicinal materials, and obtaining extract by alcohol soaking and seeping processing; making the extract and sustained-release material into framework or coated pellets, and then putting the pellets in a hollow capsules so as to make a dispersive dosage sustained-release capsule. It can keep in-blood medicine concentration for long time; prolong curative effect and reduce toxicity and side effect, especially applied to patients suffering chronic diseases in need of long-time taking medicine, such as patients suffering from chronic lung-source heart disease.

The invention relates to a novel pharmacologic effect of a novel Rho kinase inhibitor (DL0805 derivative) with indazole as a mother nucleus, and an application of the compound in preparation of a product for preventing, alleviating and / or treating PAH and complications thereof. The DL0805 derivative has the pharmacologic effects of relaxing pulmonary artery vessels, reducing pulmonary artery pressure, treating pulmonary vascular injury caused by the PAH, recovering lung tissue functions, relieving hypertrophy and enlargement of right ventricle, treating cardiac failure and liver function damages, significantly reducing death rate of animals suffered from the PAH, and preventing and treating the PAH and complications thereof. The DL0805 derivative can be synthesized through known methods and has mature preparation processes, so that a reliable source of the compound can be provided. The compound is excellent for treating the PAH and complications thereof and can be used for preparing the product for preventing, alleviating and / or treating the PAH and the complications thereof, such as chronic obstructive emphysema, chronic pulmonary heart diseases, right heart failure, liver function damages.

The invention discloses a traditional Chinese medicine composition for treating a chronic pulmonary heart disease. The traditional Chinese medicine composition is prepared from the following raw materials by certain weight ratios: ephedra, cassia twig, rhizoma zingiberis, asarum, pinellia ternate, schisandra chinensis, white peony root, rhizoma belamcandae, semen lepidii, astragalus membranaceus, angelica sinensis, rhodiola rosea, gecko, agarwood, peach seed, flos carthami, ligusticum wallichii, salviae miltiorrhizae, spina gleditsiae, codonopsis pilosula, roasted rhizoma atractylodis macrocephalae, poria cocos and honey-fried licorice root. The traditional Chinese medicine composition has the efficacies of eliminating dampness, removing phlegm, freeing the lung, relieving asthma, nourishing the blood for tranquilization, supplementing qi and promoting the production of body fluid. The traditional Chinese medicine composition is capable of effectively treating the chronic pulmonary heart disease.

A Chinese herbal formula for treating chronic pulmonary heart disease is characterized in that composition of the Chinese herbal formula contains radix aconiti lateralis preparata, bighead atractylodes rhizome, radix paeoniae rubrathe, poria cocos, cassia twig, ginger, semen plantaginis (wrapped during decocting) and rhizoma alismatis. The above medicinal materials are weighed by weight percentage and mixed together and put into a medicine pot; cold water is added into the mixed medicinal materials and the mixed medicinal materials are immersed in cold water for 3 hours; the mixed medicinal materials are boiled with high fire and then slowly decocted with slow fire for 50-60 minutes until one bowl of a medicinal soup is decocted; three bowls of water is added and secondary decoction is continuously carried out for about 30-40 minutes; a medicinal soup is filtered, decoction is carried out until one bowl of a medicinal soup is decocted; and a medicinal soup is filtered. The medicinal soup is taken at morning, noon and night when the medicine is soup. After the medicinal soup is taken, a patient needs to lie down to take a rest for 30 min. One dose of the Chinese herbal formula is taken every day, and nine doses is a treatment course. According to the invention, the problem that present treatments of chronic pulmonary heart disease have large side effect and have no obvious treatment effects is solved. The Chinese herbal formula provided by the invention is applicable to treatment of chronic pulmonary heart disease.

The invention relates to a Chinese medicinal preparation for treating chronic lung and heart diseases and process for preparation, wherein the medicament is prepared from the following raw materials (by weight ratio): astragalus root 10-60g, dodder seed 3-40g, dried tangerine peel 5-40g, poria cocos wolf 5-50g, pinellia tuber 5-30g, Sichuan fritillary bulb 5-40g, subprostrate sophora root 5-30g, apricot kernel 5-40g, roor of sessile stemona 5-40g, white mustard seed 5-40g, baikal skullcap root 5-40g.

The invention specifically relates to a levocarnitine sesquihydrate, which belongs to the technical field of medicines. The levocarnitine sesquihydrate obtained in the invention contains one and a half crystal water and has the advantages of a high purity and good stability, having non-obvious moisture absorption and weight gain even under the condition of high humidity. The invention also relates to application of the levocarnitine sesquihydrate in preventing and mitigating myocardial damage, in mitigating and alleviating symptoms of chest pain, in treating coronary heart disease, angina pectoris, heart failure, myocardial infarction and cerebral infarction, in auxiliary treatment of renal disease, chronic pulmonary heart disease, male sterility, acquired immune deficiency syndrome, intermittent claudication, as well as acute and chronic hepatitis, cirrhosis, chronic hepatic insufficiency, muscular atrophy, diabetes and bad postpartum uterus contraction, etc.

The invention belongs to the technical field of medicine and particularly relates to a traditional Chinese medicine preparation for treating acute stage of chronic pulmonary heart disease and a preparation method thereof. The traditional Chinese medicine preparation is prepared by the following raw materials: astragalus, atractylodes, poria, loquat leaf, fritillaria, platycodon root, peach kernel, ephedra, semen lepidii. The Chinese medicine preparation is mainly effected on supporting the healthy energy, warming lung and reducing phlegm, calming heart and alleviating water retention, replenishing qi to invigorate the spleen, and invigorating the circulation of blood and removing blood stasis. Besides, the Chinese medicine preparation has obvious treatment effect on acute stage of chronic pulmonary heart disease.

The invention relates to a medicine for treating chronic pulmonary heart disease. The medicine is prepared from the following raw medicinal materials in parts by weight: 10 parts of officinal magnolia bark, 8 parts of tatarian aster root, 10 parts of ephedra herb, 12 parts of Chinese magnoliavine fruit, 8 parts of Chinese hibisci rosae-sinensis flower, 15 parts of danshen root, 14 parts of safflower, 8 parts of akebia stem and 7 parts of Chinese brake herb. The medicine provided by the invention applies the officinal magnolia bark for eliminating dampness, clearing away phlegm, depressing qi and relieving the sensation of fullness, the tatarian aster root for moistening lung and depressing qi, the ephedra herb for freeing lung and relieving asthma, and inducing diuresis to alleviate edema, the Chinese magnoliavine fruit for tonifying kidney and calming mind, the Chinese hibisci rosae-sinensis flower for clearing lung heat and phlegm fire, the danshen root for promoting blood flow to induce menstrual flow, the safflower for promoting blood flow to induce menstrual flow, and dissipating blood stases to relieve pain, the akebia stem for clearing away heart-fire to induce diuresis, and the Chinese brake herb for clearing heat and promoting diuresis. All the medicinal materials are used together to achieve the effects of promoting blood flow to induce menstrual flow, clearing heat and dampness, and treating heart and lung at the same time, and can be used for treating the chronic pulmonary heart disease effectively. A clinical experiment proves that the medicine provided by the invention can be used for treating the chronic pulmonary heart disease safely and effectively.

The invention relates to a traditional Chinese medicine for treating the chronic pulmonary heart disease. The traditional Chinese medicine comprises the following raw materials, by weight, 10-15 parts of ginseng, 10-15 parts of Radix Ophiopogonis, 10-15 parts of Chinese magnoliavine, 10-15 parts of Rhizoma Atractylodis Macrocephalae, 10-15 parts of Sappanwood, 5-8 parts of Cassia Twig, 10-15 parts of Radix Astragali, 10-15 parts of Salvia miltiorrhiza, 10-15 parts of salted aconite root, 8-12 parts of Tokay Gecko, 10-15 parts of epimeddium, 10-15 parts of Chinese yam, 10-15 parts of bitter apricot kernel, 10-15 parts of Malaytea Scurfpea Fruit, 10-15 parts of Pepperweed Seed, 10-15 parts of Stemona sessilifolia, 10-15 parts of Poria cocos, 10-15 parts of peach kernel, 10-15 parts of Common Coltsfoot Flower, 5-8 parts of fried licorice, 10-15 parts of lumbricus and 10-15 parts of Herba Houttuyniae. The traditional Chinese medicine for treating the chronic pulmonary heart disease of theinvention has the advantages of simple preparation method, easily controlled quality, high cure rate, difficult recurrence, and no toxic side effect.

The invention discloses a traditional Chinese medicine composition for treating a chronic pulmonary heart disease, and belongs to the field of a traditional Chinese medicine. The traditional Chinese medicine composition has the effects of benefiting qi and nourishing blood, supporting the healthy energy, moistening the lung to remove dryness, promoting blood circulation and enhancing the immunity, and the chronic pulmonary heart disease can be cured. The traditional Chinese medicine composition is prepared from the following Chinese medicinal raw materials in parts by weight: 5-10 parts of fructus lycii, 8-12 parts of manyprickle acanthopanax root, 3-8 parts of radix pseudostellariae, 1-5 parts of polygonatum kingianum, 1-5 parts of codonopsis pilosula, 5-10 parts of mulberry fruit, 1-3 parts of humulus scandens, 1-5 parts of snakegourd fruit, 4-8 parts of eriobotrya japonica, 3-8 parts of lily, 1-3 parts of bupleurum, 3-8 parts of white peony root, 3-8 parts of cynomorium songaricum and 2-8 parts of gingko leaves. The traditional Chinese medicine composition is applicable to being taken by a patient with the chronic pulmonary heart disease, the recovery rate is 92.2%, and the total effective rate is 97.4%.

The invention relates to application of compound puerarin in the preparation of drugs for preventing, relieving and / or treating pulmonary arterial hypertension and complications thereof. A large amount of clinical practice shows that the puerarin is good in curative effect on the pulmonary arterial hypertension and is an ideal compound for treating the pulmonary arterial hypertension and the complications thereof, and the puerarin can be used for preparing products for preventing, relieving and / or treating lung injury diseases caused by the pulmonary arterial hypertension, chronic pneumonia and exogenous materials and unexplained pulmonary arterial pressure increasing and complications thereof such as chronic obstructive emphysema, chronic pulmonary heart disease and cardiac failure.

The invention discloses an electuary for treating chronic pulmonary heart disease. The electuary is prepared from the following raw medicinal materials in parts by weight: 2-7 parts of rhizoma dioscoreae nipponicae, 3-9 parts of lalang grass rhizome, 1-5 parts of balanophyllia sp, 10-20 parts of rust-coloured crotalaria herb with roots, 15-30 parts of sea-buckthorn, 5-10 parts of bulbus fritillariae cirrhosae, 13-18 parts of liquorice, 20-30 parts of lilies, 6-12 parts of pericarpium citri reticulatae, 15-40 parts of lotus plumule, 40-60 parts of snow pears and 5-15 parts of rock candies. The electuary disclosed by the invention has the functions of treating chronic pulmonary heart disease, tonifying spleen and kidney, promoting qi to activate blood, relieving cough and reducing sputum, relieving chest stuffiness and pain and enhancing the immunity. The medicinal materials are easily available in source, so that the electuary is low in cost, and almost selected medicinal materials are matters with mild drug properties, so that the electuary drunk and nourished on a long-term basis no longer increases the economical and physical burdens of a user.

The invention relates to new pharmacological effects of a compound pinocembrin and an application of pinocembrin to preparation of products for preventing, relieving and / or treating pulmonary hypertension and complications thereof. Pinocembrin has the beneficial effects that pinocembrin has the pharmacological effects of relaxing pulmonary arteries, reducing the pulmonary artery pressure, protecting pulmonary vessels from injuries caused by pulmonary hypertension, restoring lung tissue functions, repairing heart and liver injuries, alleviating right ventricular hypertrophy and enlargement, improving heart failure and liver functions, obviously reducing the mortality of animals with pulmonary hypertension and preventing and treating pulmonary hypertension and complications thereof; pinocembrin is an active monomer separated from a natural product propolis, achieves complete synthesis at present, has good application and development prospects, is an ideal compound for treating pulmonary hypertension and complications thereof and can be applied to preparation of the products for preventing, relieving and / or treating pulmonary hypertension and complications thereof, such as chronic obstructive emphysema, chronic pulmonary heart diseases, right heart failure and liver function injuries.

The invention provides a traditional Chinese medicinal preparation for treating a chronic pulmonary heart disease and a preparation method thereof. The traditional Chinese medicinal preparation comprises the following medicinal raw materials: salviae miltiorrhizae, safflower, polygonum cuspidatum, polygonatum odoratum, radix glehniae, fructus psoraleae, prepared monkshood slice, astragalus membranaceus, turmeric, adenophora tetraphylla, epimedium and liquorice. A tablet is prepared by grinding the salviae miltiorrhizae, sieving the salviae miltiorrhizae to obtain fine powder, decocting the other components, filtering, concentrating to obtain an extract, performing spray-drying to obtain extract powder, mixing the fine powder and the extract powder, and performing granulation, drying, tidying granules, tabletting, coating, subpackaging, and packaging to obtain a finished product; a capsule is prepared by grinding the salviae miltiorrhizae, sieving to obtain fine powder, decocting the other components, filtering, concentrating to obtain an extract, performing spray-drying to obtain extract powder, mixing the fine powder and the extract powder, performing granulation, drying, mixing all materials, and performing filling, subpackaging, and packaging to obtain a finished product. The traditional Chinese medicinal preparation provided by the invention is free of adverse reactions and high in safety; the medicinal raw materials are cheap, and easy to obtain, so that the economic burden of a user taking the traditional Chinese medicinal preparation for a long time is low.

The invention discloses a traditional Chinese medicine effective part composition for treating a chronic pulmonary heart disease. The traditional Chinese medicine composition comprises the following raw materials in certain weight part: sedum sarmentosum, flos daturae, gemma agrimoninae, hypericum japonicum, cortex periplocae and deer sinew. The traditional Chinese medicine effective part composition has the effects of warming lung, reducing phlegm, activating blood, warming yang to promote diuresis, activating blood to remove blood stasis, clearing heat, resolving turbidity, restoring Yang from collapse, tonifying qi, restoring the pulse, and tonifying kidney and spleen, has remarkable curative effect on the treatment of the chronic pulmonary heart disease, has no side effects, and is high in safety.

The invention belongs to the technical field of medicine, and relates to a composition for treating the acute stage of the chronic pulmonary heart disease. The composition is prepared from, by weight, rhizoma chuanxiong, pterocephalus hookeri heck, angelica sinensis, rhizoma anemarrhenae, lotus leaf, fructus forsythiae, semen lepidii and radix glycyrrhizae. The composition is good in comprehensive effect and convenient to use. The result obtained through clinical tests quite clearly shows that the composition can effectively treat the chronic pulmonary heart disease and has clinical popularization value.

The invention discloses Qinggan Bufei Ge powder and a preparation method thereof. The powder is composed of root bark of white mulberry, apricot kernel, black fungus and powdered kudzuvine root; the materials are processed into superfine powder, the superfine powder is mixed well, treated with steam and dried, and is cooled and pulverized into fine powder, and the fine powder is subjected vacuum hermetic packaging and microwave sterilization. The Qinggan Bufei Ge powder is edible, is effective in purging lung to relieve asthma, inducing diuresis to alleviate edema, clearing lung to discharge fire, clearing liver and tonifying lung and the like, is effective in enhancing physique, and has a good dietary function for chronic pulmonary heart disease so as to keep human health.

The invention relates to a traditional Chinese medicine preparation for treating chronic pulmonary heart disease. The traditional Chinese medicine preparation is prepared from semen lepidii, schisandra chinensis, radix aconiti carmichaeli, dried ginger, rhizoma atractylodis macrocephalae, herba leonuri, poria cocos, apricot kernels, sesame seeds, mulberry leaves, ginseng, honey-fried loquat leaves, pollen, radix polygonati officinalis, antelope horn, radix ophiopogonis, pear peels, platycodon grandiflorum, flos chrysanthemi and radix stemonae. After being taken, the medicine acts on heart and lungs through stomach, liver and kidneys; most of the medicinal materials act on the kidney channel, heart channel and lung channel mainly, and the medicinal materials mutually draw strength one another and have complementary effects to achieve the effects of controlling infection, smoothing the respiratory tract, improving cardio-pulmonary functions, correcting anoxia and carbon dioxide retention, correcting breath and heart failure, correcting acid-base imbalance and electrolyte disturbance, reducing pulmonary artery pressure and alleviating pulmonary edema, so that diseases can be effectively treated, complications can be effectively prevented and controlled, such as occurrence of upper gastrointestinal hemorrhage, renal insufficiency, pulmonary encephalopathy, DIC and other symptoms, and the aim of healing chronic pulmonary heart disease can be finally achieved.

The invention relates to a traditional Chinese medicine preparation for treating chronic pulmonary heart diseases. The traditional Chinese medicine preparation is prepared from the following raw traditional Chinese medicines of 15 grams of radix astragali, 10 grams of heterophylly falsestarwort roots, 4 grams of hippophae rhamnoides fruits, 5 grams of radix gentianae macrophyllae, 6 grams of lilybulbs, 3 grams of Chinese galls, 4 grams of safflowers, 3 qian of peach kernels, 4 grams of licorice roots, 10 grams of coix seeds, 9 grams of white mulberry root bark, 5 grams of herba ephedrae, 5 grams of human placenta, 2 grams of sandalwood, 9 grams of holboellia latifolia canes and fruits, 4 grams of fructus aurantii, 5 grams of combined spicebush roots, 3 qian of communis amoora tetrapetala,6 grams of dutchmanspipe vines, 10 grams of radix acanthopanacis senticosi, 3 grams of pilose antlers, 4 grams of akebia stems, 3 grams of rush, 10 grams of mulberries, 6 grams of radix ophiopogonis,10 grams of longan aril, 5 grams of buckeye seeds, 5 grams of resina liquidamberis, 10 grams of caulis spatholobi, 3 fen of draconis resin, 3 qian of fluorite and 4 grams of pimpinella thellungiana wolff. During treatment, the traditional Chinese medicine preparation can be dialectically increased and decreased according to diseases, for patients suffering from lung heat and cough caused by dryness, 10 grams of rhizoma anemarrhenae and 10 grams of polyporus umbellatus are increased; and for patients suffering from insomnia, 15 grams of indian bread with hostwood and 10 grams of radix polygalae are increased. The traditional Chinese medicine preparation disclosed by the invention is prepared form purely traditional Chinese medicines, and can treat both manifestation and root cause of diseases, and the treatment effects can directly reach the focus of a disease.

The invention belongs to the technical field of medicine, and specifically relates to a levocarnitine sesquihydrate compound. The levocarnitine sesquihydrate obtained in the present invention contains one and a half crystal waters, and has the advantages of high purity and good stability, even in Hygroscopic weight gain is not obvious under high humidity conditions. The present invention also relates to the use of this hydrate to prevent and reduce myocardial damage, relieve and relieve chest pain symptoms, and treat coronary heart disease, angina pectoris, heart failure, myocardial infarction, cerebral infarction, and kidney disease. , chronic pulmonary heart disease, male infertility, acquired immunodeficiency syndrome, intermittent claudication, etc., as well as adjuvant treatment for acute and chronic hepatitis, liver cirrhosis, chronic liver insufficiency, muscle atrophy, diabetes, postpartum uterine contraction wait.

The invention relates to new pharmacological effects of a compound pinocembrin and an application of pinocembrin to preparation of products for preventing, relieving and / or treating pulmonary hypertension and complications thereof. Pinocembrin has the beneficial effects that pinocembrin has the pharmacological effects of relaxing pulmonary arteries, reducing the pulmonary artery pressure, protecting pulmonary vessels from injuries caused by pulmonary hypertension, restoring lung tissue functions, repairing heart and liver injuries, alleviating right ventricular hypertrophy and enlargement, improving heart failure and liver functions, obviously reducing the mortality of animals with pulmonary hypertension and preventing and treating pulmonary hypertension and complications thereof; pinocembrin is an active monomer separated from a natural product propolis, achieves complete synthesis at present, has good application and development prospects, is an ideal compound for treating pulmonary hypertension and complications thereof and can be applied to preparation of the products for preventing, relieving and / or treating pulmonary hypertension and complications thereof, such as chronic obstructive emphysema, chronic pulmonary heart diseases, right heart failure and liver function injuries.